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Abstract: HIV/AIDS stands as a global burden, and vaginal microbicides constitute a promising
strategy for topical pre-exposure prophylaxis. Preceding the development of a microbicide containing
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), in silico and in vitro studies were
performed to evaluate the physicochemical characteristics of both drugs, and to study their biophysical
impact in lipid model systems. Results from these pre-formulation studies defined hydrogels as
adequate vehicles to incorporate TDF-loaded liposomes and FTC. After studying interactions
with mucin, zwitterionic liposomes with a mean diameter of 134 ± 13 nm, an encapsulation TDF
efficiency of approximately 84%, and a transition temperature of 41 ◦C were selected. The chosen
liposomal formulation was non-cytotoxic to HEC-1-A and CaSki cells, and was able to favor TDF
permeation across polysulfone membranes (Jss = 9.9 µg·cm−2·h−1). After the incorporation of
TDF-loaded liposomes and FTC in carbomer hydrogels, the drug release profile was sustained
over time, reaching around 60% for both drugs within 3–6 h, and best fitting the Weibull model.
Moreover, liposomal hydrogels featured pseudoplastic profiles that were deemed suitable for topical
application. Overall, the proposed liposomal hydrogels may constitute a promising formulation for
the vaginal co-delivery of TDF/FTC.
Keywords: drug release; emtricitabine; hydrogels; liposomes; microbicides; nanomedicine; tenofovir
disoproxil fumarate; topical PrEP
1. Introduction
Since the beginning of the epidemic, HIV has infected more than 77 million people and caused
around 35 million deaths [1]. By 2017, the Joint United Nations Program on HIV/AIDS (UNAIDS)
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estimated that 36.9 million people worldwide were infected with the virus, and that the female
population accounted for more than half of these infections. In addition, sexual transmission remains
the leading cause of new infections [2]. Although considerable progress has been made since
antiretroviral (ARV)-based therapies were introduced, HIV/AIDS stands as an increasing global health
concern, and new prevention strategies to prematurely fight and control the virus dissemination are
needed [3]. Recently, ARVs have been explored for oral and topical pre-exposure prophylaxis (PrEP) in
HIV-negative individuals before exposure to the virus [4].
Oral PrEP with tenofovir-based regimens is currently available in many countries worldwide
and is already considered a well-established preventive strategy [5]. The once daily administration of
a combination of 300 mg of tenofovir disoproxil fumarate (TDF) and 200 mg of emtricitabine (FTC),
available commercially as Truvada® (Gilead, Foster City, CA, USA), has been the most commonly used
regimen. Conversely, no topical PrEP product is available. Apart from efficacy issues, the preference for
oral PrEP is highly correlated with the fact that oral administration is convenient, discreet, and relatively
affordable [6]. However, low patient adherence to daily regimens and ARVs poor pharmacokinetic
profiles and side effects may still compromise the success of oral PrEP and decrease efficacy [5].
Also, the need for the persistent daily intake of ARVs may be regarded by some populations as
cumbersome, making on-demand products, i.e., requiring administration/application around the time
of sexual intercourse, more attractive [7]. Topical microbicides, particularly those of vaginal use,
arose as an interesting approach for topical PrEP in alternative to the oral regimens, and their protective
effect in women, although modest, was indeed observed in previous clinical trials for a tenofovir
gel [8] and a dapivirine ring [9,10]. Vaginal microbicides are intended for preventing male-to-female
transmission of the virus and act at the early stages of infection, namely at the cervicovaginal mucosa.
The relatively high local ARV drug concentrations—which can be rapidly achieved upon vaginal
administration of a microbicide—and negligible systemic exposure are regarded as advantageous
features when comparing to oral PrEP [4]. Despite all mentioned advantages, vaginal drug delivery
is challenging. Various formulation and delivery approaches have been tested, ranging from more
‘traditional’ drug dosage forms (e.g., vaginal tablets, gels, and creams) to more ‘advanced’ systems
(e.g., vaginal rings). The development of nanotechnology-based systems, in particular, is thought to
hold the potential to improve the prophylactic performance of ARV drugs by providing their sustained
release and sustaining protective concentrations at the mucosa [11]. Furthermore, the possibility of
modulating specific drug targeting through, for example, functionalization of the nanosystem surface,
is also possible [12].
Lipid-based nanocarriers have been extensively explored for vaginal drug delivery for the treatment
of fungal and bacterial diseases [13–15], as well as viral infections by human papillomavirus (HPV) [16]
and herpes simplex virus type 2 (HSV-2) [17]. However, the application of lipid formulations in HIV
prophylaxis is sparse, and few research groups investigated their potential to act as nanomicrobicides
for the vaginal delivery of ARVs. Among the first reports is the study from Caron et al. [18] in rhesus
macaques infected with a recombinant simian immunodeficiency virus containing the RT coding
region from HIV-1 (RT-SHIV), in which liposomes loaded with the nonnucleoside reverse transcriptase
inhibitor (NNRTI) MC1220 were developed, and further included in a carbomer hydroxypropyl
cellulose and glycerol mixture gel for vaginal administration. Vaginal administration was made with
a single application of liposomal gels with 0.5% and 1.5% of MC1220, or by applying a 0.5% gel for
four days. Intermediate protection against SHIV challenge was observed with all the administered
formulations. However, the higher concentration of MC1220 failed to increase the protection levels,
which was probably related with MC1220 low solubility. In another study, Alukda et al. [19] prepared
solid lipid nanoparticles functionalized with polylysine–heparin for the vaginal delivery of tenofovir.
A low drug loading was obtained (~0.1%), which was probably due to tenofovir hydrophilic character.
Additionally, the formulation did not exhibit in vitro cytotoxicity up to concentrations of 0.9 mg·mL−1.
Overall, solid lipid nanoparticles demonstrate interesting properties, but further studies with more
lipophilic or hydrophobic drugs were deemed necessary. Furthermore, Malavia et al. [20] assessed the
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antiviral activity of different plain liposomes composed with naturally occurring and synthetic lipids.
Even if the intrinsic activity of liposomes against HIV-1 was relatively low, at least to be considered as
single active agents, this study indicates that selected formulations may be interesting carriers for use
in vaginal PrEP approaches.
All in all, available studies have shown the potential to invest in lipid formulations for topical HIV
PrEP. Also, the success of Truvada® in oral PrEP seems to indicate that TDF/FTC may be an interesting
drug combination for advancing this particular delivery strategy [21]. Previous reports on animal and
human studies of vaginal rings containing TDF/FTC seem to support that the combination is useful
for topical PrEP [22–24]. Thus, the aim of the current work is the development of a putative topical
microbicide based on a liposomal hydrogel containing TDF/FTC. A preliminary study conducted to
evaluate the interaction of these drugs with lipid membrane models highlighted their distinct needs in
terms of carriers. TDF was shown to be well distributed in lipid bilayers, while causing no disturbance
regarding the biophysical stability of liposomes. Contrastingly, FTC was shown able to yield strong
biophysical impairment at the polar headgroups of lipid bilayers, which indicated that liposomes were
not adequate carriers for this drug. Therefore, the final formulation consisted of liposomes loaded
with TDF and further incorporated in carbomer-based hydrogels with FTC. Such a final dosage form
was chosen due to its good acceptability by women, technological versatility, and low manufacturing
cost, although some limitations, in particular messiness or leakage, are well recognized [25]. These last
problems can usually be minimized by simply using lower volumes of gel per administration.
To the best of our knowledge, this is the first study proposing the combination of lipid nanocarriers
and hydrogels for the intravaginal co-delivery of TDF and FTC. Particular to this work are the
pre-formulation and formulation studies that allowed a better understanding of the physicochemical
properties of the considered drugs under vaginal conditions and, consequently, planning of the rational
development of the formulation in order to select the most suitable vehicles to deliver TDF and FTC.
2. Materials and Methods
2.1. Materials
Zwitterionic—1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero
-3-phosphocholinephosphatidylcholine (DSPC), cationic—dioctadecyldimethylammonium bromide
(DODAB), and anionic lipids—1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG), as well
as cholesterol (CHOL) were obtained from Avanti Polar Lipids Inc. (INstruchemie, Delfzyl,
The Netherlands). TDF, a prodrug of the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir,
was purchased from Kemprotec (Cumbria, UK), and the nucleoside reverse transcriptase inhibitor
(NRTI) FTC was purchased from Sequoia Research Products (Pangbourne, UK). Carbomer 2001
(PFC®) was provided by Guinama Laboratories (Valencia, Spain). Purified type II mucin from porcine
stomach and thiazolyl blue tetrazolium bromide (MTT) were acquired from Sigma-Aldrich (St. Louis,
MO, USA). All other materials and solvents were provided by Merck (Kenilworth, NJ, USA) and were
of analytical grade or equivalent.
2.2. In Silico Studies
TDF and FTC biopharmaceutical properties are relevant information when selecting the most
suitable liposomal vehicle. To this end, in silico pre-formulation studies were carried out using
the Chemaxon® software (ChemAxon, Budapest, Hungary) integrated with the MarvinSketch®
mode (ChemAxon, Budapest, Hungary). The chemical structure of both drugs was introduced,
and chemical descriptors such as size, geometry, lipophilicity, ionization, solubility, and surface
topology were determined.
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2.3. Preparation of Liposomes and Liposomal Hydrogels
Liposomes were prepared by the classical thin film hydration method [26–28]. Briefly, lipids were
dissolved in chloroform, and the organic solvent was evaporated at 37 ◦C under a constant nitrogen
stream to obtain a dry lipid film. The film was further hydrated with ultrapure water, above the
lipid main phase transition temperature. Afterwards, the lipid suspension was vortexed to yield
multilamellar vesicles (MLVs) with a final concentration of 4 mM. Large unilamellar vesicles (LUVs)
were then prepared by extrusion (10 passages) of the MLVs suspension through polycarbonate filters
with a pore size of 100 nm (Millipore SAS, Molsheim, France). Extrusion was also processed at
a temperature above the lipid main phase transition temperature (Table 1).
Table 1. Lipid composition of the different liposomal formulations used throughout the
work as well as the concentration and hydration and extrusion temperature used for their
preparation. CHOL: cholesterol; DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine, DMPG:
1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol, DODAB: dioctadecyldimethylammonium bromide,
DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine, DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine,
DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholinephosphatidylcholine, TDF: tenofovir
disoproxil fumarate.
Type of Studies Lipid Composition Concentration (mM)
Temperature Used in
Hydration and
Extrusion Process (◦C)
Mucoadhesion studies
Zwitterionic liposomes:DMPC
0.4
40
Anionic liposomes:DMPG 40
Cationic liposomes:DODAB 60
Encapsulation of TDF (40 µM)
DOPC
DOPC:CHOL (7:3) 4 Room temperature
DOPC:CHOL (6:4)
DMPC
DMPC:CHOL (7:3) 4 40
DMPC:CHOL (6:4)
DPPC
DPPC:CHOL (7:3) 4 55
DPPC:CHOL (6:4)
DSPC
DSPC:CHOL (7:3) 4 65
DSPC:CHOL (6:4)
For mucoadhesion studies, liposomes with different surface charges: zwitterionic (composed by
DMPC), anionic (composed by DMPG), and cationic (composed by DODAB) were prepared according
to the classical thin film hydration method, followed by extrusion as described above.
For TDF encapsulation, zwitterionic liposomes were developed by using different lipids sharing
the same zwitterionic headgroup region (phosphatidylcholine) but comprising different saturated
fatty acids, namely myristic acid (CH3(CH2)12COOH), palmitic acid (CH3(CH2)14COOH), stearic acid
(CH3(CH2)16COOH), or the unsaturated oleic acid (CH3(CH2)7CH=CH(CH2)7COOH). Formulations of
each lipid composition (DMPC, DPPC, DSPC, and DOPC) were also prepared without cholesterol
and with 30% or 40% cholesterol. Table 1 presents a summary of all the liposomes prepared and the
experimental conditions used.
To determine the most effective encapsulation procedure, TDF-loaded zwitterionic liposomes were
prepared using three different methodologies, all conducting to a final TDF concentration of 40 µM:
(i) thin film hydration, (ii) incubation, and (iii) direct mixing. In the first, the lipid film was prepared as
described above, and hydration of the lipid film was achieved by the addition of an aqueous solution
of TDF above the lipid main phase transition temperature. In the case of incubation method, TDF was
added to LUVs that were prepared as described previously. The encapsulation of TDF by the direct
mixing method was conducted by co-drying the lipid organic solution with an ethanolic drug solution.
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Then, the resulting lipid–drug film was hydrated, and liposomes were prepared as mentioned above.
A schematic representation of the encapsulation methods is presented in Supplementary Materials
(Figure S1).
Carbomer 2001 (0.5% w/w) was used as a gelling agent in order to prepare hydrogels for
vaginal administration. Briefly, the polymer was dispersed in ultrapure water under constant stirring,
being further neutralized with triethanolamine (≈0.13% w/w) to promote gelation. Liposomes containing
TDF were directly included into the gel by replacing part of the external phase with the aqueous
dispersion of lipid colloidal carriers (10% w/w). To prepare FTC-loaded hydrogels, the drug was first
dissolved in ultrapure water in order to obtain a final concentration of 7.19 × 10−4 M. Then, the polymer
was added to the external phase, being further neutralized with triethanolamine to promote gelation.
2.4. Small-Angle and Wide-Angle X-ray Scattering (SAXS/WAXS)
To assess the order and packing of lipid bilayers, X-ray measurements were conducted at the
Austrian SAXS/WAXS beamline at the synchrotron light source ELETTRA (Trieste, Italy) employing
a monochromatic synchrotron radiation with wavelength of 0.15 nm.
The studied samples consisted of non-extruded DPPC lipid suspensions without the drugs,
with TDF, with FTC, and TDF:FTC (3:2 w/w). The drugs were co-solubilized with DPPC in a mixture
of chloroform/methanol (9:1 v/v) to obtain the desired drug:lipid molar fraction (1:9). The final lipid
concentration in each sample was approximately 15–20% w/v. After the total dissolution of the
compounds, the lipid suspensions were prepared as previously described [29] and later transferred into
X-ray transparent glass capillaries with 1.5-mm diameter (Hilgenberg, Malsfeld, Germany), which were
flame-sealed and stored at 4 ◦C until measurement.
P-bromo benzoic acid (WAXS) and silver behenate (SAXS) patterns were recorded using a Pilatus
100K 2D and Pilatus 1M detector system, respectively, with a pixel size of 172 µm at positions that
covered the typical diffraction spacing range (s = 2sinθ/λ, where λ is the wavelength and 2θ is the
scattering angle) of interest. The diffraction spacings were calibrated using the lamellar peaks of silver
behenate (SAXS) and p-bromo benzoic acid (WAXS) as standards. Static exposures were taken below
and above the main transition temperature as controlled by a thermostated water bath (stability± 0.1 ◦C;
Unistat CC, Huber, Offenburg, Germany) in order to obtain the diffraction patterns typical of DPPC
lipid phases (Lβ′ and Lα) and evaluate the effect of drugs in such phases. Data analysis was made as
described elsewhere [30].
2.5. Attenuated Total Reflection–Fourier Transform Infrared (ATR-FTIR)
The effect of TDF and FTC in the microviscosity of lipid formulations was evaluated by ATR-FTIR
to characterize the vibrational frequencies of chemical groups representative of the main phospholipid
regions (hydrophilic head, hydrophobic fatty acid tail, and an interfacial area between head/tail).
Briefly, 50 µL of each sample was added to crucibles made of aluminum foil, and the aqueous solvent
was evaporated in order to form a lipid film. The measurements were conducted by pressing the lipid
film against the crystal from the ATR accessory (refraction index = 2.4; penetration depth = 1.66 µm)
in a Spectrum Two Spectrometer (Perkin-Elmer, Waltham, MA, USA). Spectra were recorded in the
spectral range of 400–4000 cm−1, with increments of 4 cm−1 and 16 scans per spectrum.
2.6. Dynamic Light Scattering (DLS) Applied to Microviscosity Studies
DLS measurements using a ZetaSizer Nano ZS (Malvern Panalytical, Malvern, UK) were carried
out to evaluate the effect of TDF (40µM) in the main phase transition temperature (Tm) and cooperativity
(B) of DPPC liposomes (4 mM), as previously reported [30,31].
The samples were heated from 25 ◦C to 55 ◦C, with intervals of 0.5 ◦C. Measurements were made
at each temperature with a previous stabilization time of 60 s. The data obtained was expressed
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as mean count rate (MCR) versus temperature (T), and the results were fitted following a modified
Boltzmann equation:
MCR = m1 + b1T +
m2 −m1 + b2T − b1T
1+ 10B (
1
T− 1Tm )
(1)
where m1 and m2 are the slopes of the linear fits to the data before and after the phase transition region,
respectively, and b1 and b2 are the corresponding y-axis intercepts.
2.7. Mucoadhesion Studies
In order to assess the mucoadhesive properties, liposomes (400 µM) with different surface charges
(positive, negative, and neutral) (Table 1) were evaluated regarding their size (diameter), polydispersity
index, and zeta potential before and after incubation with a mucin suspension (0.4 mg·mL−1). The mean
hydrodynamic diameter (Z-average) and polydispersity index (PDI) were measured by DLS using
a ZetaSizer Nano ZS at a fixed backscatter angle of 173◦. Z-average and PDI values were obtained
from the correlogram by the ZetaSizer Nano ZS software (Malvern Panalytical, Malvern, UK) after
cumulative analysis. Zeta potential was measured by electrophoretic light scattering (ELS). In this
case, a Dip cell® (Malvern Panalytical) was introduced in polystyrene cells, and the zeta potential
values were calculated from the conversion of electrophoretic mobility according to the method of
Helmholtz–von Smoluchowski [32].
Furthermore, the quenching effect of the different charged systems was evaluated on the intrinsic
fluorescence of mucin. The fluorescence measurements were carried out on a Perkin-Elmer LS 50B
fluorimeter, using an excitation wavelength of 270 nm and an emission range of 300 to 500 nm.
2.8. Encapsulation Efficiency
The encapsulation efficiency (EE%) was determined using centrifugal filter devices with a MW
cut-off of 100 kDa (Amicon® Ultra, Millipore, Burlington, MA, USA). The EE% of TDF was calculated
by the difference between the total amount of drug used to prepare the formulation and the amount of
free drug remaining in the aqueous phase. Briefly, one milliliter of the lipid formulation containing
the drug was transferred to the filter units, which were further centrifuged in a Hettich Universal
320 centrifuge (Vlotho, Germany) at 3000 rpm for approximately 20 min. The unentrapped drug was
able to diffuse into the filtrate, and its content was quantified using a UV-2501 PC spectrophotometer
(Shimadzu, Kyoto, Japan) at 200–400 nm. The EE% was determined using the following equation:
EE% =
[TDF]total − [TDF] f ree
[TDF]total
× 100 (2)
The amount of TDF was quantified at a wavelength of 260 nm (εTDF = 13570 M−1·cm−1)
by a validated UV/Vis spectrophotometry method according to the International Conference on
Harmonization (ICH) Q2(R2) guideline using a Shimadzu UV-2501 PC spectrophotometer.
2.9. Liposomal Size, Polydispersity Index, and Zeta Potential
The Z-average and PDI of liposomes (free or loaded with TDF) and zeta potential were determined
by DLS and ELS, as described in Section 2.7. Before measurements, liposomal samples were diluted in
ultrapure water (3:7 v/v) to attain suitable scattering intensity. All measurements were performed at
25 ◦C to mimic shelf-stability conditions.
2.10. In Vitro Drug Release Studies
In vitro studies were performed in order to evaluate TDF and FTC release profiles from their
final dosage form following the dialysis bag (SnakeSkin 3500 Da MWCO, Thermo Fisher Scientific,
Eindhoven, The Netherlands) diffusion method. The dosage forms tested were the hydrogel containing
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FTC (designated as FTC@HG) and the hydrogel containing liposomes loaded with TDF (designated as
(DPPC+TDF) @HG).
Briefly, 2 mL of each dosage form was transferred to dialysis bags; afterwards, they were immersed
in 15 mL of ultrapure water, which was used as a receptor medium. The receiving phase was incubated
in a thermostatically controlled shaking (120 rpm) water bath at 37 ◦C. At pre-determined time intervals,
one milliliter of the receptor medium was removed and replaced with the same volume of fresh medium
to maintain sink conditions. The amount of TDF or FTC released from the dialysis bag was quantified
at wavelengths of 260 and 280 nm, respectively (εTDF = 13,570 M−1·cm−1 and εFTC = 9160 M−1·cm−1),
by a validated UV/Vis spectrophotometry method according to the International Conference on
Harmonization (ICH) Q2(R2) guideline using a Shimadzu UV-2501 PC spectrophotometer (Shimadzu,
Kyoto, Japan).
The studies were conducted over 7 h (considered as representative of the time period around
sexual intercourse), and results were presented as the cumulative percentage of released compound
versus time. The in vitro release profiles were fit with different mathematical models (GraphPad Prism®
software, San Diego, CA, USA) to evaluate the release kinetic profile and elucidate about the mechanisms
that control drug release [33]. Considered models were: first-order, Higuchi, Korsmeyer–Peppas,
and Weibull. The model with the highest value of adjusted coefficient of determination was selected as
the best fit to the drug release profile.
2.11. In Vitro Permeation Studies
A comparison between the in vitro permeation of non-encapsulated drug (designated as TDF)
and encapsulated TDF (designated as DPPC+TDF) was carried out in a Franz Cell system (V-Series
Stirrers, PermeGear, Hellertown, PA, USA) with a diffusion area of 0.64 cm2.
Briefly, the system was maintained at a constant temperature of 37 ◦C using a water bath.
Samples (800 µL) were transferred to the acceptor compartment, and a predefined volume of ultrapure
water (5 mL) was used as receptor medium. The drug permeation rate was measured using a synthetic
polysulfone membrane placed between the two compartments. At pre-determined time intervals (0, 1,
2, 4, 6, 8, 24 h), aliquots of 400 µL of the receptor medium were removed and replaced with the same
volume of fresh medium to maintain sink conditions. The amount of drug that permeated through
the membrane was quantified using a UV-2501 PC spectrophotometer at 200–400 nm, as described in
Section 2.8.
Permeation parameters were interpreted from the cumulative amount of released drug per unit
membrane area (QR/A) versus time (t) plot. The gradient and x intercept of the linear portion of the
plot yielded steady-state flux (Jss) and lag time (tL), respectively. Jss (µg·cm−2·h−1) was calculated by
the following equation:
JSS =
QR
At
(3)
where t (h) is permeation time, A (cm2) is permeation area, and QR (µg) is permeated amount of drug.
The drug permeability Kp (cm·h−1) was calculated by the following equation:
KP =
JSS
Cd
(4)
where Cd is the initial concentration in the donor chamber (µg·cm−3).
2.12. Rheological Behavior of Hydrogels
After mechanical and thermal equilibration, hydrogels (designated as HG) and liposomal hydrogels
(empty: DPPC@HG; or loaded with both drugs: (DPPC+TDF)/FTC@HG) were sheared in an EVO
Expert L series Rotational Viscometer (FungiLab, Hauppauge, NY, USA) at a shear rate adequate for
the spindle used to obtain the flow patterns. Gel apparent viscosity and shear stress were recorded as
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a function of shear rate. Each hydrogel was stirred for one minute at each shear rate (0, 2, 4, 6, 8, 10,
12 rpm), and the corresponding forward and backward rheograms were recorded, thus allowing the
examination of flow curves and the possible existence of hysteresis loops.
2.13. Cytotoxicity Studies
The in vitro toxicity of drugs (FTC and TDF) and liposomes (unloaded: DPPC or DODAB or
loaded with TDF: DPPC+TDF or DODAB+TDF) to human cervical CaSki and endometrial HEC-1-A
cell lines (ATCC, Manassas, VA, USA) was assessed using the MTT metabolic viability assay. CaSki cells
were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) and HEC-1-A cells in McCoy’s
5A modified medium (Invitrogen), respectively. In both cases, media was supplemented with 10% (v/v)
fetal bovine serum (Merck Millipore, Burlington, MA, USA), 100 U·mL−1 penicillin (Merck Millipore)
and 100 µg·mL−1 streptomycin (Merck Millipore). Cells were maintained under routine conditions
(37 ◦C, 5% CO2, and 95% RH), while media were changed 2–3 times weekly.
Briefly, cells were initially seeded in 96-well plates (104 cells/well) and left in culture for 24 h.
Afterwards, cells were incubated for 24 h with drugs or liposomes (plain or drug-loaded) dispersed in
media. Then, the cells were washed twice with phosphate-buffered saline and incubated for 4 h with
medium containing 0.5 mg·mL−1 of MTT. The resultant formazan crystals were dissolved with 200 µL
of dimethyl sulfoxide, and cell viability was measured using a plate reader at the absorbance of 570 nm
(readings at 630 nm were used for background deduction). Plain medium and 1% (v/v) Triton X-100 in
media were used as negative and positive controls, respectively.
3. Results
3.1. Pre-Formulation Studies
Pre-formulation studies are a stepping stone in the rational development of an effective formulation,
and several factors should be considered during this process. It is crucial to initially evaluate and
conduct a comprehensive study of the physicochemical and biopharmaceutical properties of considered
drugs [34], which can be achieved by in silico approaches. In addition, understanding the formulation
targets as well as the barriers they impose is of major importance and may dictate new approaches in
the formulation development process, such as drug–membrane interaction studies. These are also of
use in providing better knowledge of the drugs and guiding the development of formulation [29,35].
3.1.1. In Silico Studies
Relevant physicochemical properties of TDF and FTC (Figure 1) were predicted in silico (Table 2)
and subsequent inferences about their ionization, lipophilicity, permeability, and solubility, as well as
their classification according to the Biopharmaceutical Classification System (BCS), were made.
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Figure 1. Three-dimensional (3D) chemical structures of tenofovir disoproxil fumarate (TDF)
and emtricitabine (FTC). Chemical structures were generated with ‘Chemicalize’ tool from
Chemaxon® software.
Table 2. In silico prediction of several physicochemical descriptors obtained from TDF and FTC
chemical structure using Chemaxon® software.
Drug MW (g·mol−1) PSA (Å2) VWSA (Å2) logP S (mg·mL−1) pKa H Donors H Acceptors
TDF 635.52 185.44 753.35 2.65 1.24 3.75 1 10
FTC 247.24 88.15 279.83 -0.90 7.67 1.75 2 5
Abbreviations: logP—log10 of the octanol/water partition coefficient; S—intrinsic aqueous solubility; MW—molecular
weight; pKa—negative log10 of the ionization constant; PSA—polar surface area; VWSA—Van der Waals surface area.
Regarding the FTC ionization profile, the calculated pKa value (pKa = 1.75) was lower than
the experimental value reported previously (pKa = 2.65) [36]. The pKa of FTC was correlated with
the ionization of the primary amine functional group (Figure 1, amine bounded to the heterocycle
group in FTC). However, according to the Henderson–Hasselbalch equation, the experimental pKa of
2.65 corresponds to a very low dissociation constant (Kb = 4.47 × 10−12). Considering the theoretical
value obtained, the FTC dissociation constant will be even lower (Kb = 5.62× 10−13), thus indicating that
the ionization of the primary amine is unlikely to occur. This is particularly relevant when considering
physiological conditions, since such low pH values are not observed at the vagina, neither pre-ejaculation
(pH = 3.5−4.5) or post-ejaculation (pH = 7.0−8.5) [37]. The theoretical pKa of TDF agreed with the
experimental value (pKa = 3.75) [36]. Although there may be a predominance of a positively
charged TDF isoform at lower physiological pH values due to the amine group protonation (Figure 1,
amine bounded to the heterocycle group in TDF), it is anticipated that TDF will be predominately in
the non-ionized state at relevant pH values expected for topical vaginal administration.
According to the Lipinski “rule of five”, it is more likely for a compound to exhibit poor
permeability if at least two of the following characteristics are observed: LogP >5; molecular weight
(MW) >500 Da; H donors >5 and H acceptors >10 [38]. Thus, FTC fulfills the requirements for
presenting good permeability, while TDF is expected to have permeability issues given its high
MW and number of H acceptors groups (Table 2). Regarding lipophilicity, TDF and FTC are quite
different. Moreover, FTC can be classified as hydrophilic (logP < 0), while TDF is moderate lipophilic
(0 < logP < 3). However, concerning aqueous solubility, both drugs are predictably water-soluble
(>1 mg·mL-1).
The good permeability of FTC places this compound in BCS class I, which is in agreement with
official classification [39]. However, one should also consider the FTC hydrophilic nature, which may
qualify it as a BCS class III drug, which is actually in agreement with a recent revision of the BCS
classification [40]. TDF is only moderately lipophilic, and due to its poor permeability, it can be classified
as a class III drug, which is also in agreement with its reported classification [39,40]. Thus, both drugs
may benefit from formulation strategies that can improve their permeability and enhance tissue
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penetration, namely to the level of the epithelium and lamina propria, where most HIV-susceptible
cells are located [41]. Moreover, the higher polarizability and higher affinity of TDF drug to lipidic
environments (demonstrated by PSA and logP values in Table 2, respectively) may compromise its
capacity to diffuse in cervicovaginal mucous fluids. Indeed, PSA values refer to the surface area of the
oxygen and nitrogen atoms; thus, high PSA values suggest that TDF may be highly polarized and
able to interact with mucins by hydrogen bonding [42,43]. The moderate lipophilic character of TDF
can also contribute to non-specific binding to hydrophobic domains of mucins, which may further
reduce its diffusion in mucus [44]. Therefore, TDF would benefit from its encapsulation in nanocarrier
systems, such as liposomes, that protect the drug from interacting with mucins and potentially enhance
its distribution across mucus. Liposomes have an amphiphilic character that can provide the necessary
lipophilic environment for TDF encapsulation, while displaying hydrophilic surface that promotes
transport in mucus. On the contrary, FTC is highly hydrophilic, thus not constituting a problem for
cervicovaginal mucus transport, but can contribute to its premature leakage from the vaginal cavity.
Thus, hydrogels seemed to be an interesting approach to increase FTC retention in the vagina, given the
viscoelastic nature of such systems and their typical mucoadhesive behavior [25].
In summary, drug properties predicted by in silico studies helped us decide on the development
of a carbomer-based hydrogel containing FTC and liposomes loaded with TDF as a potential
vaginal microbicide.
3.1.2. Drug–Membrane Interaction Studies
Molecules with an intracellular mechanism of action such as TDF and FTC need to bypass
the membrane of HIV-susceptible cells in order to reach the cytoplasm. There, these drugs can be
phosphorylated into their active forms and compete with endogenous nucleotides to terminate the
formation of viral DNA [45]. In this context, their ability to interact with cellular membranes may
further dictate the ability of both TDF and FTC to penetrate or even distribute in the genital tract.
Phosphatidylcholines, including the palmitoyl derivative (DPPC), are phospholipids commonly
used to mimic the physicochemical and biological properties of cellular membranes [46].
Membrane model systems made of DPPC exhibit many features of the cellular membranes (e.g.,
the barrier and transport function, or permeability by passive diffusion through the bilayer).
Drugs may alter phospholipidic membrane properties, namely its structure, lipid-packing parameters,
and microviscosity [35]. In this regard, the effects of TDF and FTC in different DPPC lipid phases
were evaluated by SAXS and WAXS diffraction patterns, providing information on the bilayer
structure and lipid packing through the respective measurement of long and short spacing (d values).
Since lipid bilayer organization, thickness, and phospholipids packing are temperature dependent,
the measurements were conducted at 20 ◦C and 55 ◦C in order to assess the effect of TDF and FTC on
the gel (Lβ′ ) and fluid (Lα) phases of DPPC, respectively.
Typical SAXS patterns (Figure 2) were obtained for Lβ′ and Lα phases of fully hydrated DPPC
in good agreement with our previous reports [47]. The lamellar long spacing (bilayer thickness,
including a water layer between the bilayers) was determined in each lipid phase from the SAXS
patterns of DPPC, and the values are presented in Table 3.
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Figure 2. Small angle X-ray diffraction silver behenat (SAXS) patterns of DPPC (black) or DPPC
containing TDF (yellow), FTC (blue), or TDF and FTC (3:2 w/w) (green) measured in the Lβ′ (A) and
Lα (B) phases of DPPC.
Table 3. Long spacings (dL) and correlation length (ξ) determined from SAXS patterns and short
spacings (dS) determined from p-bromo benzoic acid (WAXS) patterns of DPPC without or with FTC,
TDF, and FTC+TDF (3:2 w/w) in the Lβ′ and Lα phases.
Lipid Bilayers in the Absence
or Presence of Drugs
Long-Spacing Values (SAXS) 1
Short-Spacing Values
(WAXS)
dL 1 (Å) ξ dS (Å) dS (Å)
Lβ′ Lα Lβ′ Lα Lβ′ Lβ′
DPPC 62.91 65.15 1084 1018 4.25 4.11
DPPC + FTC 51.80 54.21 41 24 4.21 4.11
DPPC + TDF 62.70 68.14 96 688 4.24 4.14
DPPC + FTC + TDF 53.36 53.55 41 42 4.19 4.11
1 The spacings were calculated for the first reflection order Bragg peak.
The diffraction peaks of the DPPC membranes in the absence of the drugs presented a small full
width of the peaks at one-half of their intensity (FWHM), indicating a good correlation between the
bilayers (see values of correlation length ξ in Table 3). This correlation was affected by the addition of
either TDF or FTC. However, the effect of each drug in the membrane structure was quite different.
TDF has the least disturbing effect on membrane structure, as it only slightly increased the long-spacing
value in the Lα phase. This event may result in modifications in DPPC hydration due to interactions
with TDF. Furthermore, the ξ values in the Lα phase, although reduced in comparison with native
DPPC layers, were still high, thus indicating that the drug insertion does not disturb the structure of
the lipid bilayers (Table 3). The long-space value of DPPC in the Lβ′ phase was not notably changed
upon the addition of TDF, but a larger reduction of ξ indicates a higher disturbance effect of this drug
on membrane structure.
The addition of FTC to the lipid system led to a noticeable breakdown of the multilamellar
correlation (decrease ξ values in comparison with DPPC without drug, as shown in Table 3),
thus manifesting the greater disturbance effect of this drug on the membrane structure. In both
phases, the inclusion of FTC promoted a decrease in long-spacing values, which indicates a decrease in
the thickness of the lipid bilayer plus the hydration layer. This decrease might be due to a fluidizing
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effect of the drug in the lipid bilayer, resulting in a reduction in the bilayer thickness and/or to a decrease
in the water layer.
The WAXS diffraction patterns for DPPC demonstrated an asymmetric double Bragg peak (d20
and d11 in Figure 3) that is characteristic of a pseudo-hexagonal tilted chain packing occurring in the
Lβ′ phase.
Figure 3. Wide angle X-ray diffraction (WAXS) patterns of DPPC or DPPC containing TDF, FTC,
or TDF and FTC (3:2 w/w) measured in the Lβ′ phase of DPPC. Solid red lines give the best fit of the
Lorentzian’s analysis model (dashed lines) to the scattered intensities. A model of drug–membrane
interaction is proposed for each diffractogram together with the resultant chain packing.
The WAXS pattern of the addition of FTC to the Lβ′ phase showed a superposition of two chain
packings. One resulted from a least perturbed lipid phase, where an intermediate tilt angle persists
(peaks d20 and d11 and chain-packing scheme in Figure 3), and the other corresponded to a hexagonal
chain packing resulting from the most influenced regions of the drug. Due to FTC’s hydrophilic
nature, its insertion probably occurs at the headgroup region, causing a change in the area requirement
of the headgroups, thus allowing the chains to be oriented in a hexagonal untilted chain packing
(peak d10 and chain packing scheme in Figure 3). The insertion of FTC at the polar headgroup region
could be further confirmed by the calculation of the lipids’ cross-sectional area (A0). An A0 of the
20.41 Å2/aliphatic chain was determined for DPPC, and was in good agreement with data previously
reported [30]. The addition of FTC to DPPC reduced the A0 to the 20.15 Å2/aliphatic chain, ruling out
the possibility of drug penetration within the aliphatic core of the membrane [48]. The addition of
TDF to the Lβ′ phase promoted an approximation of the two Bragg peaks (peaks d20 and d11 and
chain-packing scheme in Figure 3), suggesting that TDF is able to intercalate within the phospholipids
and reduce their tilt angle. Upon the insertion of TDF, the lipid cross-sectional area suffers a slight
increase (from 20.41 Å2 to 20.44 Å2). This indicates that the drug is also able to penetrate the aliphatic
core of the membrane, being however well accommodated within the lipid chains, and thus not causing
a great perturbing effect of the lipid packing. When both drugs are added to DPPC membranes,
the effects observed were very similar to those of FTC addition.
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The impact of TDF and FTC in the microviscosity of DPPC membranes was further evaluated by
ATR-FTIR. The results obtained by this technique may be confronted with SAXS and WAXS in the Lβ′
phase, since measurements were made at room temperature (below the Tm of DPPC). According to the
vibrational frequencies obtained for the different chemical bonds of DPPC phospholipids (Figure 4A),
multiple structural and biophysical information can be predicted upon interaction with drugs [49,50]:
order of the phospholipid hydrocarbon tail assigned to υ(CH2) stretching modes with bands between
2800–3000 cm−1 (Figure 4B); lipid packing assigned to CH2 scissoring vibration mode (δ(CH2)n) with
bands between 1300–1600 cm−1 (Figure 4C); hydrogen bonding or hydration capacity assigned both
to phosphate headgroups (PO2) with bands between 1200–1260 cm−1 (Figure 4D); and to interfacial
carbonyl groups (C=O) with a band close to 1736 cm−1 (Figure 4E). Calculation of the band areas ratio
at 1221 and 1200 cm−1 (a1221/a1201), assigned to the νas(PO2) stretching mode is also important to infer
about the degree of hydration of the headgroup region. Increase of this ratio indicates dehydration or
ion pair formation [50].
Figure 4. (A) DPPC phospholipid showing the chemical groups responsible for the main infrared
vibration modes; (B–E) show attenuated total reflection–Fourier transform infrared (ATR–FTIR) spectra
obtained for DPPC membranes in the absence (black) or in the presence of TDF (yellow) or FTC (blue)
for different vibration modes: υ(CH2) stretching modes (B); δ(CH2)n scissoring vibration mode (C);
υas(PO2) stretching mode (D); and υ(C=O) stretching mode (E). In panel (D), dashed lines represent
the deconvolution of the bands performed to determine with precision the area of the band located at
1221 cm−1 required to subsequent calculation of the ratio a1221/a1201.
ATR-FTIR data indicates that FTC is able to induce higher effects in DPPC membranes,
thus confirming the SAXS and WAXS results. It was possible to observe a shift of the CH2 symmetric
(υs(CH2)) and asymmetric (υas(CH2)) stretching mode to higher frequencies (Figure 4B) in the presence
of FTC, which is indicative of an increase of gauche rotamers accompanied with a more conformational
disordered phase [51,52]. This confirms the hypothesis that FTC has a fluidizing effect in the lipid
bilayer, thus justifying the reduction in the bilayer thickness observed in SAXS (Table 3). The CH2
scissoring vibrational mode of DPPC exhibits two characteristic peaks (Figure 4C) of an orthorhombic or
pseudo-hexagonal tilted chain packing [49,50]. In agreement with WAXS data (Figure 3), FTC provoked
the higher change in lipid packing, and the CH2 scissoring vibrational mode appeared as a singlet
typical of a hexagonal lattice [49,50]. Regarding their position, the PO2 bands did not seem to be
significantly affected by the drugs. However, analyzing the ratio of band areas (a1221/a1201) at the
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PO2 stretching modes (area of the bands at 1221 cm−1 and 1201 cm−1 in Figure 4D), it was possible to
distinguish the effect of the drugs: a1221/a1201 of DPPC was 0.30, while the addition of TDF or FTC
increased this ratio to 0.38 and 0.49, respectively. Such an increase indicated that dehydration or ion
pair formation occurred [50], thus confirming the interaction of both drugs at the headgroup region
that was already apparent from WAXS measurements. Furthermore, FTC, which is expected to interact
mainly with the polar lipid headgroups, had the larger effect. The dehydration occurring in the Lβ′
phase observed by ATR-FTIR can explain the reduction in d values observed for both drugs in SAXS
studies. On one hand, the drugs reduced the tilt and led to an increase in d values due to a more
upright position of the acyl chains (Figure 3); on the other hand, the compounds induced a decrease in
the water layer (as proved by an increase in a1221/a1201) that resulted in a decrease in the value of d.
Both effects can compensate for each other, leading to a d value that, in the case of TDF, was closer to
the d value of DPPC (Table 3). In the case of FTC, greater dehydration (as proved by an increase in
a1221/a1201) together with a fluidizing effect (as proved by the shift of CH2 stretching modes to higher
frequencies) can justify the accentuated d value decrease observed in SAXS (Table 3). Finally, the C=O
stretching mode of DPPC at 1737 cm−1 was slightly shifted to lower frequencies (1735 cm−1) upon the
addition of either FTC or TDF, which suggests that the drugs established hydrogen bonding to this
group (Figure 4E).
Overall, ATR-FTIR and SAXS/WAXS measurements revealed that the interaction of FTC with
DPPC bilayers promoted a decrease in bilayer thickness plus the water layer, and demonstrated to
be highly disruptive of the lipid packing. Thus, despite being quite hydrophilic, FTC was able to
interact with lipid polar headgroups, thus leading to dehydration and having a disruptive effect on
lipid packing. This reinforces that FTC should not be considered for encapsulation in liposomes.
Although TDF also interfered with lipid packing, its impact was smaller and more pronounced in
DPPC gel phase (Figure 2A). Indeed, TDF moderate lipophilicity allowed for a better distribution of the
drug within the lipid membranes, thus contributing to a minor impact in DPPC bilayers organization
as compared to FTC. SAXS studies have also shown that fluid lipid systems may be less disturbed by
TDF incorporation (Figure 2B) than ordered ones (Figure 2B). These conclusions further support the
choice of liposomal formulations as adequate nanocarriers for TDF incorporation.
3.1.3. Mucoadhesive Properties of Liposomes with Different Surface Charges
The diffusion of a drug nanocarrier through mucus depends not only on its diameter (should
be up to around 500 nm) but mostly on the ability to establish adhesive interactions with
mucins [53]. Electrostatic, hydrogen, and/or hydrophobic bonding can be established depending on
the surface physicochemical properties of nanosystems. Although traditionally regarded as beneficial,
mucoadhesion impairs the transport of nanomaterials in mucus. Thus, mucus-inert nanosystems have
been considered as advantageous in order to allow better drug distribution and even retention in the
vaginal cavity [54].
Varying liposome composition may allow modulating their interaction with mucins.
Therefore, we started by studying the interaction of cationic, zwitterionic, or anionic liposomes
with mucin by assessing the hydrodynamic diameter (Z-average) and zeta potential of the lipid systems
before and after incubation with mucin in suspension (Figure 5).
Pharmaceutics 2019, 11, 485 15 of 27
Figure 5. The effect of the surface charge of liposomes in zeta potential (A) and hydrodynamic diameter
or Z-average (B), before (indicated by the letter B in x-axis) and after (indicated by the letter A in x-axis)
interaction with a mucin suspension. Fluorescence emission spectra of mucin before interaction with
liposomes and after interaction with cationic, anionic, or zwitterionic liposomes are presented in (C)
(spectra follow the same color code used in bars of panels (A,B)).
Cationic liposomes presented a significant decrease of zeta potential in the presence of mucin,
down to values close to neutrality (Figure 5A), thus suggesting that interaction with mucin occurred
mainly by adsorption to liposomes. Electrostatic interactions between positively charged amino
quaternary groups of liposomes and negative sialic acid residues of mucin are likely involved.
As a result, charge neutralization led to the formation of large aggregates, as evidenced by the increase
in Z-average (Figure 5B). In the case of anionic liposomes, an increase in zeta potential was observed
(Figure 5A) but without charge neutralization. This adds the possibility of the establishment of other
type of interactions, namely of hydrophobic nature. Also, enduring negative surface charge was
still sufficient to maintain liposomes in suspension due to the maintenance of electrostatic repulsion
between vesicles (Figure 5B), as observed before for other type of negatively-charged nanosystems [55].
Finally, zwitterionic liposomes displaying in their headgroup region both positively (choline) and
negatively (phosphate) charged groups observed a decrease in zeta potential from close to neutrality to
negative values upon incubation with mucin (Figure 5A). In this case, positively charged choline likely
interacted with the negatively charged sialic groups of mucin, leading to a prevailing of negatively
charged phosphate groups at the surface of liposomes (Figure 5A). Also, the resulting net surface
charge after incubation with mucin was able to avoid aggregation (Figure 5B).
We further complemented charge and size data by measuring the decrease in the intrinsic
fluorescence of mucin upon incubation with the different type of liposomes. Close proximity or
interaction between liposomes and fluorescent residues of mucin (namely tryptophan) are able
to decrease overall fluorescence [56]. Fluorescence studies confirmed that all types of liposomes
were able to interact with mucin (Figure 5C). Furthermore, it was possible to correlate the previous
size and zeta-potential results with fluorescence quenching. Cationic liposomes interacted with
mucin exclusively by electrostatic interactions, which probably occur at the surface without reaching
tryptophan residues, and thus causing milder decrease in fluorescence. Quenching was more
pronounced for anionic and zwitterionic liposomes, given that electrostatic interactions are possibly
not the main mechanism of interaction with mucin, and hydrophobic interactions may account for the
higher fluorescence quenching of tryptophan residues.
Overall, the data obtained indicate that positively charged liposomes are likely to exhibit less
mobility in mucus by establishing strong electrostatic interactions with mucin. Conversely, low-affinity
adhesive interactions with hydrophobic regions of anionic and zwitterionic liposomes may allow
these last regions to feature enhanced transport in mucus, even if still featuring some degree of
mucoadhesiveness. Our results are also in agreement with previous reports on the transport of
differently charged nanosystems, including liposomes, in mucus or mucus surrogates [55,57].
Considering the putative advantages of having a nanocarrier that features, at least to some extent,
enhanced transport across mucus, we discarded cationic liposomes for the encapsulation of TDF.
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The choice between negatively charged or zwitterionic liposomes, which displayed similar interaction
with mucin, relied on previous reports that the zwitterionic nature of nanosystems (including several
biological entities such as viruses) may further be advantageous when considering mucus transport [58].
Hence, zwitterionic liposomes were the only type considered for formulation studies.
3.2. Formulation Studies
3.2.1. Physicochemical Characterization
Zwitterionic formulations with a common phosphatidylcholine (PC) headgroup and with different
fatty acids (DMPC, DPPC, DSPC, and DOPC) were prepared without cholesterol and with 30% or 40%
cholesterol (Table 1), and TDF was encapsulated in these formulations by different methodologies
(hydration, incubation, and direct mixing, as represented in the Supplementary Materials, Figure S1).
The main goal of testing different formulations was to assess how liposomes of different fluidities
influence the encapsulation of TDF. The full results for the initial studies on EE% obtained
for different methodologies of encapsulation and for different formulations are included in the
Supplementary Materials (Figure S2). Values of EE% were generally high (74–89%), irrespective of
the encapsulation method or the liposomal composition. All formulations/methodologies allowed
producing liposomes with narrow sizes (134 ± 13 nm) and low PDI values (0.12 ± 0.06), thus suggesting
the existence of monodisperse populations. The zeta-potential values of such liposomes varied between
−10 and +10 mV, as expected for zwitterionic liposomes.
The evaluation of possible changes in the microviscosity of the liposomal formulation upon drug
encapsulation was also required, as it is a helpful parameter to be considered in the choice of the
most adequate formulation. For example, if including the drug in the liposomal formulation alters
considerably its microviscosity, it can result in the liposomal system becoming too fluid to carry the
drug during the required time after administration, and the lipid composition should perhaps be
revised to convey more rigid domains [29]. Microviscosity changes induced by TDF encapsulation in
lipid formulations of different fluidity (DMPC, DPPC, DSPC) were further evaluated by determining
Tm (main phase transition temperature at which the liposomes undergo conformational changes from
the gel phase to the fluid phase) and B (cooperativity of the phase transition, which provides evidences
if the drug is homogeneously distributed). Results are included in the Supplementary Materials
(Table S1). Overall, TDF encapsulation in different liposomes did not induce substantial changes to
the microviscosity of lipid bilayers, thus indicating that none of the considered formulations were
destabilized by drug incorporation.
In order to reduce the number of formulations being further evaluated, and since no formulation
was shown to be particularly advantageous over the others, we decided to select only liposomes
composed by DPPC. This lipid presents an intermediate fluidity and it also represents a prominent
component of mucus phospholipids of cervicovaginal mucosa [59]. Also, pre-formulation studies were
conducted by studying the interactions of TDF with liposomes composed by DPPC. The EE%, size, PDI,
zeta-potential and biophysical parameters (Tm, B) of TDF-loaded DPPC liposomes are summarized
in Table 4.
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Table 4. Physicochemical and biophysical characterization of empty DPPC liposomes and DPPC
liposomes loaded with TDF by different methods (incubation, hydration, and direct mixing), including:
Encapsulation efficiency (EE%), mean hydrodynamic diameter (Z-average), polydispersity index (PDI),
zeta potential, main phase transition temperature (Tm), and cooperativity of the phase transition (B).
R2 is the coefficient of determination of Tm and B after fitting data with Equation (1).
Type of
Characterization
Parameters Evaluated DPPC
DPPC+TDF
Incubation Hydration Direct Mixing
Physicochemical
EE (%) - 84.63 ± 5.09 ns 87.31 ± 4.68 ns 84.79 ± 6.51 ns
Z-average (nm) 123.97 ± 3.62 113.13 ± 0.38 ns 113.47 ± 1.07 ** 129.83 ± 6.69 **
PDI 0.11 ± 0.01 0.06 ± 0.01 ** 0.10 ± 0.01 *** 0.24 ± 0.01 ***
Zeta potential (mV) −3.55 ± 0.29 +6.00 ± 0.28 *** +0.80 ± 0.33 *** −5.29 ± 0.280 ns
Biophysical
Tm 41.05 ± 0.03 41.19 ± 0.05 ns 41.27 ± 0.02 ns 41.49 ± 0.03 ns
B 2781 ± 234 4117 ± 724 ns 3922 ± 238 ns 3135 ± 298 ns
R2 0.999 0.999 0.999 0.999
Results are the mean ± standard deviation of at least three independent measurements, and comparisons were
performed using one-way ANOVA with the Tukey–Kramer post-test for the following paired observations: (1) EE%
obtained with the incubation method vs. EE% obtained with the hydration method; EE% obtained with the
hydration method vs. EE% obtained with the direct mixing method; EE% obtained with the direct mixing method
vs. EE% obtained with the incubation method; (2) Z-average, PDI, zeta potential, Tm, or B of: liposomes of DPPC
loaded with TDF by the incubation method vs. liposomes of DPPC loaded with TDF by the hydration method;
liposomes of DPPC loaded with TDF by the hydration method vs. liposomes of DPPC loaded with TDF by the
direct mixing method; liposomes of DPPC loaded with TDF by the direct mixing method vs. liposomes of DPPC
loaded with TDF by the incubation method; *** p < 0.001; ** p < 0.01; * p < 0.05; ns, not significant.
All the different encapsulation methods demonstrated high and similar TDF EE% in DPPC
liposomes correspondent to a total drug loading (ratio between the concentration of drug encapsulated
and lipid concentration) of about 1%. The different preparation methods demonstrated similar
mean diameters ranging between 113–130 nm. These values are considered suitable for allowing
transport within the mucin mesh spacing in vaginal mucous fluids [60]. The PDI values were also
low, regardless of the encapsulation method used and varied in the range of 0.06–0.24, thus indicating
the presence of homogeneous and monodisperse liposome populations. Additionally, zeta-potential
values within −10 and +10 mV confirmed the net neutral surface charge of the vesicles due to the
balance of choline and phosphate residues present in the headgroup region of DPPC.
The experimental Tm value obtained (Table 4) for DPPC was in accordance with previous reported
studies [47]. Additionally, neither the presence of TDF nor the encapsulation method used had a major
impact in the Tm of DPPC, with a maximum variation of 0.44 ◦C observed upon the incorporation of TDF.
The cooperativity of the phase transition of DPPC was high (2781 ± 234), indicating that the transition
of lipid molecules to different phases occurred identically throughout the lipid bilayer, and at the same
time, an uncommon increase in the cooperativity of the transition was observed in the presence of TDF.
This may occur under circumstances where a compound penetrating the lipid bilayer has a planar
non-bulky structure that is capable of parallel alignment to the phospholipids [61]. Thus, TDF not
only did not disturb lipid packing, but also favored it by establishing van der Waals interactions with
phospholipids. These results are in agreement with SAXS and WAXS results, which have shown that
TDF is able to penetrate the aliphatic core of the membrane, but can still be well accommodated within
the lipid chains, not affecting lipid packing.
Altogether, these results indicate that liposomes of DPPC are suitable for TDF encapsulation,
since they feature: (i) high encapsulation efficiency (≈85%) for a total drug loading of ≈1%;
(ii) adequate size and surface charge in order to allow at least partial transport across mucus;
and (iii) structural stability, since liposomes are not fluidized by TDF incorporation, and their Tm is
kept over physiological temperature.
3.2.2. Pharmaceutical Performance of the Selected Formulation
Following the selection of TDF-loaded liposomes, we proceed with the in vitro evaluation of
several parameters that are important predictors of the pharmaceutical performance. The proposed
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formulation, based in a hydrogel containing FTC and liposomes loaded with TDF, was tested for (i)
drug permeation across a synthetic membrane simulating the epithelial barrier of the genital mucosa;
(ii) the release profile of bioactive compounds; (iii) the rheological properties (which govern, at least
partially, in vivo spreading and retention, as well as drug release behavior); and (iv) toxicity to relevant
genital cell lines.
HIV-susceptible immune cells are mainly located at the sub-epithelial compartment of the
cervicovaginal mucosa. TDF and FTC need to permeate the epithelium in order to reach this site
and interact with such cells. The ability of FTC to penetrate the female genital tract is known to be
greater than that of TDF, which has been related with the ability of the drug to inhibit its cell efflux [45].
Moreover, FTC is also able to interact with the lipid polar headgroups and lead to dehydration and
a disruption of lipid packing, as shown in our drug–membrane interaction studies. This behavior may
ultimately favor mucosal penetration through lipid bilayers impairment. In this scenario, it seems that
an enhancement of membrane permeation may be particularly critical in the case of TDF, namely when
encapsulated into liposomes. Comparison of the in vitro permeation profiles for unloaded free TDF or
for TDF loaded in DPPC liposomes are shown in Figure 6A.
Figure 6. In vitro studies to evaluate the pharmaceutical performance of the developed formulation.
In vitro TDF permeation across a polysulfone membrane in the free from (TDF) or when encapsulated
in the DPPC liposomal formulation (TDF+DPPC) performed in aqueous medium at 37 ◦C (A).
Release profile of TDF from DPPC liposomes included in hydrogels ((DPPC+TDF)@HG) and
release profile of FTC from the hydrogels (FTC@HG) performed in aqueous medium at 37 ◦C
(B). Flow rheograms of hydrogels without drugs or liposomes (HG), hydrogels with drug-free
DPPC liposomes (DPPC@HG), and hydrogels containing FTC and TDF-loaded DPPC liposomes
((DPPC+TDF)/FTC@HG) (C). Viability of human HEC-1-A endometrial cell line was tested with
increasing concentrations of FTC (D), liposomes of DPPC without drug (DPPC) or loaded with TDF
(DPPC+TDF) (E), and liposomes of DODAB without drug (DODAB) or loaded with TDF (DODAB+TDF)
(F). Concentrations in (E,F) are in TDF (real or virtual in the case of drug-free liposomes). Results are
presented as mean ± standard deviation values (n = 3). Lines in (A,B) and (D–F) represent the Weibull
model and log-logistic regression fits, respectively.
The flux of TDF in the free form across the membrane barrier was slower
(Jss = 0.717 ± 0.100 µg·cm−2·h−1), and diffusion started immediately (tL = 0). Encapsulation in
liposomes also allowed an immediate onset of TDF diffusion (tL = 0), but with an accelerated
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flux rate across the membrane barrier (Jss = 9.902 ± 0.542 µg·cm−2·h−1). Moreover, the liposomal
formulation improved TDF permeation (Kp = 0.979 ± 0· 054 cm· h−1) as compared with the free drug
(Kp = 0.07129 ± 0.001 cm·h−1). One possible explanation for this distinct permeation behavior may be
related with the large surface area of the liposomes permitting faster dispersion of the drug into the
medium, thus increasing the concentration gradient of TDF at the membrane surface and increasing
passive diffusion across this last. This enhancement in drug permeation seems interesting and indicative
that liposomes may promote TDF concentration at the mucosal level. Still, any interpretation of these
data needs to be cautious, since artificial membranes, such as the one used in our experiments, do not
entirely mimic the complex permeation phenomena observed in vivo. Nevertheless, the value of
synthetic membranes is well recognized for topical drug delivery, including by regulatory bodies
such as the FDA [62]. Another aspect of our experiments has to deal with the lack of control of pH of
the aqueous medium (≈5–6). Although deviating slightly from physiological values, TDF and FTC
are neutral in a wide range of pH (as shown above during in silico studies), and thus hydronium
concentration is unlikely to influence permeation in the considered system.
We next evaluated the release profiles of TDF from liposomes included in hydrogels and FTC from
hydrogels (Figure 6B). The incorporation of the highly hydrophilic FTC in the semisolid pharmaceutical
base allowed obtaining fast initial drug release, with 40% of the total FTC content being released in one
hour. A release plateau was further reached at about 3 h, which lasted at least up to 7 h. These results
indicate that high levels of FTC can be available for protection within a short timeframe after vaginal
administration, while a residual drug can be released in a more sustained fashion. The release of TDF
from the liposomal hydrogels was even slower and more sustained, with maximum drug levels being
observed only after 5–6 h. Such behavior may be interesting, particularly due to the beneficial effects
of liposomes in promoting permeation, as previously inferred.
The release profiles of both FTC and TDF were further adjusted to representative kinetic models,
namely first-order, Korsmeyer–Peppas, Weibull, and Higuchi [33]. The calculated release kinetics
parameters are included as Supplementary Materials (Tables S2–S5). The results of these analyses show
that the best fits to the experimental data, with R2 values above 0.99, were obtained with the Weibull
model. Accordingly, 56.5 ± 1.5% of FTC was released from hydrogels, and less time was required for
the total release, indicating a higher rate of release (i.e., a parameter was higher), while 66.1 ± 2.5% of
TDF was released from liposomal hydrogels at a slower rate of release (i.e., a parameter was lower)
(Supplementary Materials, Table S4). Naturally, the need to bypass two barriers, namely the liposomal
phospholipidic bilayer and the hydrogel matrix, may be responsible for the slower release rate of TDF
as compared to FTC. Despite the valuable information provided by in vitro release assays, the intrinsic
limitations of these studies should be taken into consideration, since several important events could
influence drug release, particularly those occurring during sexual intercourse (e.g., increase in vaginal
fluid volume, intense shear stress, presence of semen, etc.) [63].
The use of a hydrogel as a dosage form for TDF-loaded liposomes and FTC may help overcome
vaginal retention issues and allow comfortable self-administration by women [64]. The pharmaceutical
performance of hydrogels regarding in loco retention and spreading are well known to be partially
determined by the viscoelastic properties of hydrogels, and thus, rheological characterization provides
important data [65]. We obtained flow rheograms of hydrogels without drugs or liposomes (HG),
liposomal hydrogels without the presence of drugs (HG+DPPC), and hydrogels containing FTC and
TDF-loaded liposomes ((DPPC+TDF)/FTC@HG), as presented in Figure 6C. All hydrogels displayed
a typical flow curve of a non-Newtonian pseudoplastic system, i.e., viscosity decreases with the
increasing shear rate. This is in line with other vaginal gels available in the market and commonly
used by women [65]. Such behavior may favor increased spreading during high shear rate events such
as intravaginal administration and coitus. Low thixotropy (i.e., reduced hysteresis areas) indicates that,
after the cessation of high shear stress, hydrogels can rapidly and almost fully resume their consistency
and elastic features, thus promoting in loco retention. Still, some differences were noted among
formulations. The incorporation of drug-free liposomes in the hydrogel caused a noticeable increase in
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viscosity. However, such increase was less pronounced in the presence of drugs. This seems to indicate
positive and negative effects of liposomes and TDF/FTC, respectively, in the reinforcement of the
polymeric matrix that forms the hydrogel. The onset of such effects requires more studies, but may likely
be related with the electrostatic interactions between the components of the different hydrogels [66].
Similarly to our results, typical rheograms of non-Newtonian pseudoplastic behavior were also
obtained by Pavelic´ et al. [67,68], Vanic´ et al. [69], and Malana et al. [70] for carbomer-based hydrogels,
which displayed a continuous decrease of viscosity with the increase of shear rate. The rheological
behavior of poly(acrylic acid) hydrogels was also evaluated by Ferreira et al. [71]. In agreement with
our results, these researchers also demonstrated an increase in the gel viscosity upon the incorporation
of liposomal formulations. Other studies failed to demonstrate significant differences in gel viscosity
when compared with the control gels, while some of them report that the inclusion of liposomes
promoted a decrease in this parameter. This was probably due to the presence of sodium ions in the
buffer where the liposomes were prepared, which are not compatible with anionic carbomers [67,68].
Finally, we assessed the cytotoxic potential of free TDF and FTC, drug-free DPPC liposomes,
and TDF- loaded liposomes using HEC-1-A and CaSki cell lines as in vitro models of the genital
epithelium and relevance in the development of vaginal microbicides [72]. Hydrogels were not
tested, since at relevant drug/liposome concentrations, the relative amount of formulation to cell
culture medium was too high to be tested, resulting in excessive nutrient dilution and/or the high
viscosity of the mix for cell culture experiments. Figure 6D–F presents the viability of HEC-1-A cells
exposed to increasing concentrations of free FTC and different liposomes (with or without TDF).
The half-maximal cytotoxic concentration (CC50) values calculated from log-logistic regressions for
FTC were estimated to be above 100 µM (maximum tested concentration) for both considered cell lines
(Figure 6D; data not shown for CaSki cells). These results are in accordance with previously reported
studies [73]. In the case of free TDF, the toxicity potential was higher, with CC50 values of 34 µM
and 55 µM being calculated for HEC-1-A and CaSki cells, respectively (Supplementary Materials,
Figure S3). Again, these are in accordance with the reported values in the literature (22–50 µM),
and indicate the higher cytotoxicity of TDF as compared to FTC [74,75]. When considering DPPC
zwitterionic liposomes, concentrations above 10 µM in TDF could not be used due to the large amount
of corresponding liposomes (drug loading was around 1%). Still, the viability profiles for both cell lines
were similar up to at least the maximum TDF concentration considered, and thus, CC50 values could
only be estimated to be well above 10 µM (Figure 6E; data not shown for CaSki cells). This suggests
that the encapsulation of TDF in DPCC liposomes did not, at least, increase the intrinsic toxicity of
the drug. To highlight the importance of the proper selection of liposomal composition, we also
tested the cytotoxicity of cationic DODAB liposomes (Figure 6F). A typical reduction of around 2-log
in CC50 values (0.4–1.3 µM) was observed for liposomes (either containing TDF or not) in both cell
lines. Such exacerbated toxicity is likely associated with the cationic lipid component rather than
TDF. Overall, the considered DPPC liposomes presented low cytotoxicity potential, with no apparent
decrease in cell viability being observed at TDF concentrations that are at least around 200 times and 50
times higher than those required for the half-maximal inhibition of drug-susceptible or drug-resistant
HIV-1 strains, respectively [74,75].
4. Discussion
The prevention of sexual transmission remains a top priority in the fight against HIV/AIDS.
Despite all available and effective strategies, the number of infected people keeps on increasing.
The development of topical PrEP approaches, namely by developing microbicides, holds great promise,
but efficacy has been, at best, marginal. Novel formulation approaches are in demand. The present
work attempts to propose a tentative topical product that could parallel the currently available oral
PrEP with TDF/FTC. The rationale behind such approach relies on the premise that the ARVs used for
PrEP act essentially at the mucosal level in order to block early HIV-1 transmission events. The strategy
presented in this manuscript was heavily based on pre-formulation in silico, and experimental studies
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that highlighted the real ‘needs’ of the candidate drugs. Generated data guided the selection of an
adequate formulation strategy (in particular for liposomal carriers) that could comply with physiological
requirements pertaining to vaginal drug administration. We specifically proposed a novel topical
microbicide based in liposomal hydrogels for the vaginal delivery of TDF/FTC. The composite system
was further tested for important attributes that are able to determine its biopharmaceutical performance.
In silico pre-formulation studies were essential for predicting TDF/FTC physicochemical properties
under relevant physiological conditions and guiding formulation/dosage form engineering. Both drugs
presented limitations that dictated the need for suitable action. The moderate affinity to lipid
environments and high solubility of TDF indicated that a hypothetical ideal system would have
to contain both polar and nonpolar regions in order to allow drug solubilization. For this reason,
we decided to proceed with the development of liposomes. In the case of FTC, its hydrophilicity
guided our formulation efforts toward hydrogels.
SAXS, WAXS, and ATR-FTIR studies were also performed as part of the pre-formulation work.
Important structural and biophysical information on the interaction of the drugs with lipid membranes
were obtained, and helped us to better anticipate the behavior of TDF and FTC when reaching important
barriers such as the ensemble cervicovaginal epithelial cell lining or individual cell membranes.
SAXS and WAXS measurements supported TDF/FTC in silico predictions and confirmed our formulation
approach. FTC was shown to have a significant impact in the structure of membranes: the drug
caused a considerable reduction in the thickness of the bilayer, plus the hydration layer, which was
probably due to a fluidizing action. A notorious disruptive effect in lipid packing was also observed in
both gel and fluid lipid phases, which emphasizes the inadequacy of liposomes to encapsulate FTC.
Conversely, lipid nanocarriers seem to be suitable for TDF, since this compound is distributed within
the phospholipids of the lipid bilayers while causing a minor biophysical impact.
At this point, we decided that FTC should be incorporated into a hydrogel, while TDF should
be loaded in a liposomal formulation. The next step comprised the selection of a suitable liposome
composition for TDF encapsulation. Two essential parameters were studied, namely: (i) surface
charge, which may be relevant for the interaction with mucus; and (ii) lipid fluidity, which is an
important determinant of the overall physicochemical properties. Lipid fluidity was modified by
changing the length of the lipid chains or by incorporating cholesterol. In vitro studies confirmed the
strong electrostatic interaction between cationic liposomes and negatively charged mucin. Anionic and
zwitterionic liposomes also established adhesive bonding with mucin, although of lower affinity and
readily cleavable. Ultimately, zwitterionic liposomes based on DPPC appeared to be the better choice
in order to assure a good balance between mucoadhesion and mucus diffusion.
TDF-loaded zwitterionic liposomes presenting sizes around 130 nm and narrow size distribution
(PDI = 0.12± 0.06) were further prepared. The EE% was high (≈85%) and well above the values reported
previously for TDF-loaded magneto-plasmonic DPPC liposomes [76]. However, in this last case,
the higher drug-to-lipid ratios used, and the co-incorporation of magneto-plasmonic nanoparticles
into liposomes may justify differences. Other types of nanocarriers have also been proposed for
the encapsulation of TDF but lower—or, at best, similar—EE% values have been reported [77–79].
The biophysical stability of liposomes upon the incorporation of TDF was also evaluated, and the results
supported that vesicles were not fluidized by drug incorporation and that their Tm was kept over the
physiological temperature. Zwitterionic liposomes used for TDF encapsulation further demonstrated
the ability to enhance the transport of TDF across a synthetic membrane barrier (Jss = 9.902 ± 0.542 µg·
cm−2·h−1) and significantly improved TDF permeation (Kp = 0.979 ± 0.054 cm·h−1) as compared to the
free drug (Kp = 0.07129 ± 0.001 cm·h−1). Such observations were regarded as promising, and support
that liposomes may be able to enhance TDF accumulation at mucosal tissues.
Drug release studies also yielded interesting indications regarding the ability of hydrogels and
liposomes to release FTC and TDF, respectively. The ability to provide a considerable fraction of
incorporated drugs in a relatively rapid fashion may allow achieving protective levels soon after
vaginal administration. Also, slower release of the remaining drug content may allow sustaining FTC
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and TDF levels at the vagina for at least a few hours. Such a product could be particularly useful
for the pericoital protection of women engaging in occasional sexual activity. The only comparable
work focusing on a vaginal system for the co-delivery of TDF and FTC was just recently released,
and considered drug-loaded Eudragit® L 100 nanoparticles incorporated into soft polymeric films [77].
Although the rapid release of both drugs was also observed, no residual sustained release was
noted, thus reflecting the difficulty of devising a simple and common vehicle that is able to provide
biphasic release behavior for both TDF and FTC. The liposomal hydrogels were also shown to possess
appropriate rheological behavior, namely when considering vaginal administration. The viscoelastic
nature of the vehicle may be found to be useful in enhancing drug distribution and retention within
the mucosal cavity, although advanced testing (namely in vivo) is deemed necessary to confirm these
assumptions. Furthermore, the pH of the liposomal gel was slightly acidic (≈5.2) at the upper limit
of the vaginal pH range considered as normal for healthy women of reproductive age. We used
non-buffered aqueous medium as solvent for in vitro drug release studies, as neither the formulation
nor the drugs are ionized in a wide range of pH values. Thus, pH changes are unlikely to influence the
permeation/release or physicochemical characteristics in the considered system. Nevertheless, we plan
on conducting future release studies in simulated vaginal fluid.
Finally, cytotoxicity studies demonstrated that no particular safety issues may be foreseen at this
point, namely beyond those intrinsic to the incorporated drugs. Also, comparison between zwitterionic
and cationic liposomes reinforces the choice of the previous when considering the development of
microbicides. Safety is a cornerstone of the field, and even minor toxicity concerns at early stages of
microbicide development are deemed unacceptable [80].
Overall, this research work represents, to the best of our knowledge, the first hydrogel-based
formulation containing simultaneously FTC and TDF-loaded liposomes for vaginal administration and
intended for topical PrEP. Although additional studies are required and envisioned—namely in vitro
ARV activity, transport analysis of liposomes in the gel and mucus, ex vivo permeability, and in vivo
pharmacokinetics, safety, and efficacy evaluation—the proposed formulation constitutes a potentially
useful tool for advancing the microbicides field.
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